Not actually a Placebo controlled trial, which is acknowledged further into the press release. There was randomisation, regarding which dose was given.
"The data are being presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference (AIDS 2020: Virtual) and include a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19."
From http://investors.gilead.com/news-releases/news-release-details/gilead-presents-additional-data-investigational-antiviral
A very radically different death rate to that reported in earlier trials where the difference was not statistically significant, why the difference?
The only numbers given out to 28 days are for a group of pediatric patients, the table included in the news article only goes out to 14 days, whereas the FDA really wants the data out to 28 days, all causes mortality.
I guess this will be clarified shortly.
Cell Therapy News/Articles, page-4159
-
- There are more pages in this discussion • 14,160 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12214 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 37660 | 5 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |